Search

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more

Highlights from the SWG

EHA2023 CongressThe EHA2023 Congress was held in Frankfurt, Germany, in June 2023. Guideline sessionTitle‘The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children.

Read more

15th Annual Sickle Cell and Thalassemia & 1st EHA European Sickle Cell Conference

October 26-31, 2020 | Virtual Global Conference

Steering Committee: B Andemariam, A Campbell, M Cappellini, S Chakravorty,  R Colombatti, B Inusa, R Kesse-Adu, D Rees, A Taher, M Treadwell

In the last week of October, consultants and specialist psychologists, nurses, scientists and…

Read more

15th Annual Sickle Cell and Thalassemia & 1st EHA European Sickle Cell Conference

October 26-31, 2020 | Virtual Global Conference

Steering Committee: B Andemariam, A Campbell, M Cappellini, S Chakravorty,  R Colombatti, B Inusa, R Kesse-Adu, D Rees, A Taher, M Treadwell

In the last week of October, consultants and specialist psychologists, nurses, scientists and…

Read more

International CML adherence survey launched

The drivers behind non-adherence, a highly prevalent problem in oral cancer treatments but also in many other diseases like diabetes, are not well understood to date.

Read more

Turkey tutorial focused on lymphoma

The 8th EHA-TSH Hematology Tutorial was held on April 6-7, 2019 in Izmir, Turkey. This marks yet another pleasant and fruitful collaboration between EHA and the Turkish Society of Hematology.

Read more